Welcome to our dedicated page for Fulcrum Therapeutics news (Ticker: FULC), a resource for investors and traders seeking the latest updates and insights on Fulcrum Therapeutics stock.
Fulcrum Therapeutics Inc (FULC) is a clinical-stage biopharmaceutical company pioneering therapies that address genetically defined rare diseases through precise gene regulation. This dedicated news hub provides investors and industry observers with essential updates on the company's scientific advancements and operational milestones.
Access real-time information about FULC's clinical programs, including losmapimod for facioscapulohumeral muscular dystrophy (FSHD) and pociredir for hemoglobin disorders. Our curated collection features official press releases, regulatory filings, and analysis of strategic partnerships that shape the company's trajectory in targeted therapy development.
Key updates include progress reports on clinical trials, FDA designations, research collaborations, and financial disclosures. Bookmark this page to monitor FULC's innovative approach to modulating gene expression and its potential impact on treating rare diseases with high unmet medical needs.
Fulcrum Therapeutics (Nasdaq: FULC) announced inducement equity grants for new hires under its 2022 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
The company granted an aggregate of 270,000 non-statutory stock options to two employees and a 50,000 performance-based option to a third employee, each with an exercise price of $9.02 per share (closing price on the grant effective date, Nov 3, 2025).
The 270,000 options carry a 10-year term and vest over four years (25% after one year, then 6.25% quarterly over 12 quarters). The 50,000 performance option vests after 12 months subject to continued eligibility and achievement of predefined performance objectives, and will be forfeited if objectives are not met within six months of the grant date.
Fulcrum Therapeutics (Nasdaq: FULC) will present new clinical and preclinical data at the 67th American Society of Hematology Annual Meeting on December 6–7, 2025.
Pociredir Phase 1b PIONEER results will include full data from the 12 mg cohort and initial data from the 20 mg cohort in adults with severe sickle cell disease and hydroxyurea intolerance/unresponsiveness. A poster (ID 1157) is scheduled for Dec 6 and was selected for a Poster Walk on Dec 7. Fulcrum will host a live and webcast investor event on Dec 7, 2025 at 7:00 a.m. ET.
Fulcrum Therapeutics (NASDAQ: FULC) reported Q3 2025 results and clinical updates on Oct 29, 2025. Key clinical news: encouraging Phase 1b PIONEER 12 mg cohort results showing dose-dependent fetal hemoglobin (HbF) increases, hemolysis marker improvements, total hemoglobin gains, VOC reduction trends, and no drug-related SAEs through 12 mg. Enrollment completed in the 20 mg cohort (n=12); data expected by year-end 2025. Financials: $200.6M cash and marketable securities as of Sept 30, 2025, with a cash runway into 2028. Q3 R&D $14.3M, G&A $7.6M, net loss $19.6M.
Fulcrum Therapeutics (NASDAQ: FULC) will release its third quarter 2025 financial results on Wednesday, October 29, 2025, before U.S. markets open.
Management will host a conference call and webcast on October 29, 2025 at 8:00 a.m. ET to discuss results and provide a corporate update. Participants must register to receive dial-in details and a unique PIN. An audio webcast will be available on the company’s Investor Relations website and an archived replay will be posted after the live webcast.
Fulcrum Therapeutics (Nasdaq: FULC) will present preclinical data for FTX-6274, an oral EED inhibitor, showing potential activity in castration‑resistant prostate cancer (CRPC).
The poster (ID 2504P) led by Suchi Raghunathan will be shown at ESMO Congress 2025 in Berlin on Oct 18, 2025, 12:00–12:45 PM CEST. Fulcrum noted the data highlight EED inhibition beyond its hematology programs and said a strategic partnership could best advance oncology development. The poster will be posted on Fulcrum’s Publications & Presentations page after congress publication.
Fulcrum Therapeutics (Nasdaq: FULC) announced inducement grants under Nasdaq Listing Rule 5635(c)(4) to new employees on October 6, 2025. The company granted an aggregate of 47,450 non-statutory stock options under its 2022 Inducement Stock Incentive Plan at an exercise price of $9.50 per share (closing price on the grant date).
Each option has a 10-year term and vests over four years: 25% after the first anniversary of employment and then 6.25% quarterly over the following twelve quarters, subject to continued service.
Fulcrum Therapeutics (Nasdaq: FULC), a clinical-stage biopharmaceutical company, has granted inducement stock options to a new employee. The company issued 35,000 stock options with an exercise price of $7.27 per share, matching the closing price on September 8, 2025.
The options, granted under the 2022 Inducement Stock Incentive Plan, have a ten-year term with a four-year vesting schedule. The vesting includes 25% after the first year and 6.25% quarterly over the following three years, contingent on continued employment.
Fulcrum Therapeutics (NASDAQ:FULC), a clinical-stage biopharmaceutical company developing small molecules for rare genetic diseases, has announced upcoming presentations at two major healthcare investment conferences.
The company will participate in the Cantor Fitzgerald 2025 Annual Global Healthcare Conference on September 4, 2025, and the H.C. Wainwright 27th Annual Global Investment Conference on September 9, 2025. Both events will be held in New York and feature presentations from key executives including CEO Alex Sapir, CFO Alan Musso, and SVP of Early Development Iain Fraser.
One-on-one meetings with management will be available to interested investors through conference representatives.
Fulcrum Therapeutics (Nasdaq: FULC), a clinical-stage biopharmaceutical company, has announced the granting of inducement stock options to new employees. The company issued an aggregate of 36,400 stock options with an exercise price of $6.96 per share, matching the closing price on August 4, 2025.
The options, granted under the 2022 Inducement Stock Incentive Plan, have a ten-year term and follow a four-year vesting schedule. The vesting includes 25% after the first year and 6.25% quarterly over the following three years, contingent on continued employment.
Fulcrum Therapeutics (NASDAQ:FULC) reported Q2 2025 financial results and clinical progress. The company announced promising results from the 12 mg dose cohort of the Phase 1b PIONEER trial for pociredir in sickle cell disease, showing an 8.6% mean increase in fetal hemoglobin and 67% F-cells, with no serious adverse events.
Financial highlights include $214.1 million in cash reserves as of June 30, 2025, extending runway into 2028. Q2 2025 resulted in a net loss of $17.3 million, compared to net income of $55.4 million in Q2 2024. R&D expenses decreased to $13.0 million from $17.3 million year-over-year, while G&A expenses reduced to $6.8 million from $10.2 million.
FAQ
What is the current stock price of Fulcrum Therapeutics (FULC)?
What is the market cap of Fulcrum Therapeutics (FULC)?
